Cargando…
First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer
INTRODUCTION: Cytokine release syndrome (CRS) is a potentially life-threatening systemic disease that has been observed after treatment with antibodies and adoptive T cell therapies. In this case, we observed nivolumab-induced CRS in a patient with gastric cancer. CASE PRESENTATION: A 43-year-old ma...
Autores principales: | Oda, Hiroyasu, Ishihara, Mikiya, Miyahara, Yoshihiro, Nakamura, Junko, Kozuka, Yuji, Iwasa, Motoh, Tsunoda, Akira, Yamashita, Yoshiki, Saito, Kanako, Mizuno, Toshiro, Shiku, Hiroshi, Katayama, Naoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477485/ https://www.ncbi.nlm.nih.gov/pubmed/31043953 http://dx.doi.org/10.1159/000496933 |
Ejemplares similares
-
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
por: Tono, Yasutaka, et al.
Publicado: (2018) -
Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice
por: Oda, Hiroyasu, et al.
Publicado: (2020) -
A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016) -
CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression
por: Nagano, Mayuko, et al.
Publicado: (2021) -
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)